Introduction
Despite intense focus, so far no effective treatment has been developed for severe cases of COVID-19. SARS-CoV-2 infection results in a multisystem hyperinflammatory syndrome with acute respiratory distress syndrome (ARDS), acute kidney failure, and cardiovascular and neurological complications (Wang et al., 2020). Severe cases of this condition are characterized by a “cytokine storm” and rampant inflammation (Renu et al., 2020; Ye et al., 2020). The hyperinflammation is associated with the generation and release of reactive oxygen and nitrogen species (ROS/RNS), which can further amplify inflammation (Lucas and Maes, 2013). Histopathological observation of COVID-19 has revealed diffuse alveolar damage with vascular endothelialitis, thrombosis, and intussusceptive angiogenesis (Ackermann et al., 2020). The angiocentric inflammation is not limited to the COVID-19-induced lung injury but also involves prolonged inflammation in other organs, such as the liver, brain, heart, or the gut (Ackermann et al., 2020; Wang et al., 2020). Any treatment that could limit the “cytokine storm,” reduce ROS/RNS production, and counteract the formation of thrombosis would be highly attractive, and, in the best-case scenario, such a treatment would additionally interfere with viral replication. Recently, a preliminary study reported that the administration of dexamethasone, a corticosteroid with anti-inflammatory effects, could elicit a 30% reduction in mortality for patients receiving invasive mechanical ventilation (Horby et al., 2020).
In a previous study, we screened a panel of 99 ethanolic herbal extracts for their anti-inflammatory properties. Hop (Humulus lupulus, cones) and Ceylon cinnamon (Cinnamomum verum alias C. zeylanicum, bark) extracts were found to elicit particularly drastic reductions in activation of the transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), a key regulator of pro-inflammatory cytokines (Schink et al., 2018b).
The literature search was mainly performed in MedLine. In a first round, we looked for studies describing anti-inflammatory effects for Ceylon cinnamon, hops, and their major compounds. In a second approach, we then searched for clinical studies testing the efficacy of the plants in treating human disease.
HOPS
Hops, the seed cones of the plant Humulus lupulus from the family Cannabaceae, contain several pharmaceutically active compounds, such as humulone, lupulone, and xanthohumol (Gerhäuser, 2005; Knez Hrncic et al., 2019; Lin et al., 2019). Crude hop extracts as well as individual compounds have been described to exert anti-viral effects against several DNA and RNA viruses (Buckwold et al., 2004; Fuchimoto et al., 2013). For example, humulone, the most important bitter acid of hops, can suppress replication of the respiratory syncytial virus (RSV alias Human orthopneumovirus) in cell culture by disturbing the formation of viral filaments (Fuchimoto et al., 2013). Xanthohumol from hops showed synergistic effects with IFN-α in the treatment of bovine viral diarrhea virus (BVDV), and a combination of the two substances was more effective than IFN-α or xanthohumol alone (Zhang et al., 2010).
Scientific reports on the biological effects of hops and hop compounds are not limited to anti-viral properties; anti-bacterial activity, anti-fungal properties, and anti-malarial action have also been reported (Gerhäuser, 2005; Cermak et al., 2017; Weber et al., 2019). Lupulone and xanthohumol exhibit synergistic effects with selected clinically used antibiotics (Natarajan et al., 2008).
Hops also counteract inflammation; humulone can exert an anti-inflammatory effect on the TNF-induced expression of cyclooxygenase with effective doses that are in the same order of magnitude as dexamethasone (Yamamoto et al., 2000). Moreover, humulone can inhibit Toll-like receptor 4 (TLR4) and NF-κB signaling (Yamamoto et al., 2000; Fu et al., 2016; Schink et al., 2018b). In an animal model, topically applied humulone was shown to inhibit NF-κB, AP-1, and mitogen-activated protein kinases (MAPKs) (Lee et al., 2007). Xanthohumol from hops was found to reduce the expression of IL-1β, IL-6, IL-8, and TNF in virus-infected and LPS-stimulated porcine primary alveolar macrophages (Liu et al., 2019), and hop-derived humulone and lupulone were shown to mitigate the expression of IL-6 (Weber et al., 2019).
Hop extracts are further effective in counteracting oxidative and nitrosative stress; hop compounds were shown to mitigate neural nitric oxide synthase (nNOS) activity and 3-morpholinosydnonimine (SIN-1)-induced oxidation of LDL (Stevens et al., 2002). The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is a key regulator of the expression of antioxidant genes (Yamamoto et al., 2018). Hop compounds and especially xanthohumol were shown to activate NRF2 in different studies (Dietz et al., 2005; Lee et al., 2011; Yao et al., 2015). A small, placebo-controlled, clinical study showed that a low-intake dose of 12 mg/day xanthohumol decreased oxidative stress-induced DNA damage (Ferk et al., 2016).
Xanthohumol was also shown to be effective in preventing thrombosis in animal models (Xin et al., 2017). In contrast to what has been observed for blood thinners, no increased bleeding was seen when the substance was administrated orally in two doses of 10 mg/kg xanthohumol per day for 60 days (Xin et al., 2017). The antioxidant effects of xanthohumol were also confirmed in this same study (Xin et al., 2017). Further, hops exert anti-fibrogenic effects in vitro, and specifically xanthohumol was shown to possess this property in vivo (Dorn et al., 2012; Saugspier et al., 2012).
Ceylon Cinnamon
The genus Cinnamomum belongs to the family Lauraceae and comprises more than 100 species in the NCBI Taxonomy Database. Here, we review specifically Ceylon cinnamon (Cinnamomum verum alias C. zeylanicum, NCBI:txid128608), which we have used in our studies (Schink et al., 2018a,b; Ose et al., 2020). Generally, Chinese cassia or Chinese cinnamon (Cinnamomum cassia alias Cinnamomum aromaticum) is commercially sold as a spice for foods and does not represent a risk to human health per se (Oketch-Rabah et al., 2018). However, it can comprise high amounts of coumarin, which is highly hepatotoxic in higher doses. The German Federal Institute for Risk Assessment (BfR) therefore recommends that Cassia cinnamon with high coumarin content be consumed only at moderate levels. The differences between Ceylon cinnamon and Cassia have been reviewed recently (Oketch-Rabah et al., 2018).
Ethanolic extracts of Ceylon cinnamon possess anti-inflammatory activity and antagonize TLR2 and TLR4 activation in a dose-dependent manner with minimal effects on viability in cell culture (Kanuri et al., 2009; Schink et al., 2018b). We identified several active compounds in these extracts, amongst others, trans-cinnamaldehyde, cinnamic acid, cinnamyl alcohol, cinnamyl methyl ether, p-cymene, methyl salicylate, 1-tetradecanol (myristyl alcohol), and benzoic acid. We found synergy among the anti-inflammatory properties of the different compounds: the efficacy of the complex mixture was greater than those of the pure active compounds of cinnamon (Schink et al., 2018a).
Cinnamaldehyde is an effective NRF2 inducer (Long et al., 2015) and acts in this way to detoxify ROS/RNS (Wondrak et al., 2010). Further, cinnamaldehyde can inhibit angiogenesis and metastasis via mitigation of the PI3K/Akt pathway (Patra et al., 2019). A specific inhibition of VEGFR2 kinase and of angiogenesis was shown for a water-based extract from Ceylon cinnamon (Lu et al., 2010).
In an animal model, an extract of Ceylon cinnamon was shown to protect the aorta from dexamethasone-induced atherosclerosis and minimized the atherogenic risk (Nayak et al., 2017).
Retrieved Results from Clinical Studies
We searched for clinical studies on Cinnamon using the search term “Ceylon Cinnamon OR Cinnamaldehyde,” while for clinical studies on hops we used the search term “Humulone OR Lupulone OR Xanthohumol OR hops” (Tables 2, 3). For both search terms, we restricted the results to “Clinical Trial.” For Cinnamon we obtained 123 hits, from which we excluded 57 hits, as cinnamon was not used to treat human disease in these studies. The ethanolic extract, as used in cell culture experiments, was not directly given to patients in any of the clinical studies. Rather, for the majority of clinical studies with Ceylon cinnamon, powder was administered in an encapsulated form; the clear advantage of administering Ceylon cinnamon in this way is that the formulation does not comprise ethanol. Since we cannot give here an appropriate dosage of cinnamon for the treatment of COVID-19, we refer to clinical studies that have used cinnamon to treat other conditions. Thirty of the clinical Cinnamon studies deal with diabetes, glucose levels, and insulin tolerance, five with polycystic ovary syndrome, and three with overweight and obesity. We could not find any clinical studies on “cytokine storms,” but we hypothesize that the strong anti-inflammatory properties of Ceylon cinnamon may mitigate this complication. Ranasinghe et al. evaluated the safety of Ceylon cinnamon in healthy adults, concluding that there were no significant side effects and toxicity of Ceylon cinnamon for the dosages applied (Ranasinghe et al., 2017b).
When searching for hops and compounds found in hops, we obtained 92 hits for clinical studies, from which we excluded 50 as non-matching. This is because many hits refer to the verb “to hop,” i.e., “to jump.” Eight studies are linked to sleep disorders, six to adiposity and metabolic syndrome, six to menopause, and two clinical studies are on anti-bacterial effects. Often hops are given orally as an extract (water, oil), which is frequently administered in combination with other drugs such as valerian. One study concerns specifically the use of iso-alpha-acids from hops, which include humulone, to dampen inflammation in knee osteoarthritis (Hall et al., 2008).
Taken together, among the so-far performed clinical studies on Ceylon cinnamon and hops, we could not find any that specifically described efficacy in preventing the “cytokine storm” or sepsis. However, results from diverse cell culture experiments make it likely that hops and Ceylon cinnamon may exert these effects.
Discussion
Both hop and cinnamon extracts have been shown to exert several anti-inflammatory functions (Yamamoto et al., 2000; Schink et al., 2018a,b). For instance, both can dampen the release of pro-inflammatory cytokines (Lee et al., 2007; Schink et al., 2018b; Liu et al., 2019; Weber et al., 2019). Moreover, hop and cinnamon extracts can inhibit angiogenesis, thrombosis, and vascular endothelialitis (Dorn et al., 2012; Saugspier et al., 2012; Xin et al., 2017; Patra et al., 2019). Further, these herbal extracts can activate the key regulator of the antioxidant response, NRF2, which mitigates the ROS/RNS production generally associated with inflammation (Dietz et al., 2005, 2013; Wondrak et al., 2010; Lee et al., 2011; Pinto et al., 2014; Long et al., 2015; Yao et al., 2015). Taken together, we suggest that hop and Ceylon cinnamon extracts may ameliorate complications that are associated with severe cases of COVID-19 and that testing both extracts, either alone or in combination, and particularly as a supplemental treatment to other medications, might be a promising therapeutic approach. If the preliminary results for dexamethasone can be confirmed, this glucocorticoid may be widely used to treat cases of COVID-19 (Horby et al., 2020). Supplementation with Ceylon cinnamon extract could then ameliorate the potential side effects of dexamethasone such as atherosclerosis (Nayak et al., 2017). Hop extracts exert anti-viral effects against some virus strains, but whether these extracts are also effective against SARS-CoV-2 has not yet been experimentally verified (Buckwold et al., 2004; Zhang et al., 2010; Fuchimoto et al., 2013).
Pneumonia caused by bacteria is a frequent complication after artificial ventilation (Póvoa et al., 2020; Wu et al., 2020; Zhang et al., 2020). The anti-bacterial effects of hops (Gerhäuser, 2005; Natarajan et al., 2008; Cermak et al., 2017; Weber et al., 2019) and Ceylon cinnamon (Ranasinghe et al., 2013; Vasconcelos et al., 2018; Doyle and Stephens, 2019) could act preventatively in such cases. As they are derived from common foodstuffs, both hop and Ceylon cinnamon extracts can be regarded as safe. Of course, an allergy against a hop or cinnamon ingredient or alcohol intolerance would contraindicate their intake.
It has become clear that many COVID-19 patients suffer from inflammatory complications (Heneka et al., 2020; Portincasa et al., 2020). We suggest that treatment with the here-discussed extracts could also mitigate such complications. Should cinnamon and hops prove to exert positive effects in the treatment of COVID-19, they would be readily available at low cost and can be produced at multi-ton scales. In western medicine, it is common to use pure substances rather than less well-defined herbal extracts. Of course, the individual compounds as listed in Table 1 can be used for treatment, but a certain loss of synergy may result (Schink et al., 2018a).
Table 1
| Plant | Active compound | References |
|---|---|---|
| Hops | humulone | Palamand and Aldenhoff, 1973; Gerhäuser, 2005; Knez Hrncic et al., 2019; Lin et al., 2019 |
| lupulone | Palamand and Aldenhoff, 1973; Gerhäuser, 2005; Knez Hrncic et al., 2019; Lin et al., 2019 | |
| xanthohumol | Palamand and Aldenhoff, 1973; Gerhäuser, 2005; Fu et al., 2016; Knez Hrncic et al., 2019; Lin et al., 2019 | |
| Ceylon cinnamon | trans-cinnamaldehyde | Schink et al., 2018a; Vasconcelos et al., 2018 |
| cinnamic acid | Schink et al., 2018a; Vasconcelos et al., 2018 | |
| cinnamyl alcohol | Schink et al., 2018a |
Active compounds from hops and Ceylon cinnamon.
Table 2
| Disease/condition or observed effect | Dosage form | References |
|---|---|---|
| Ceylon Cinnamon | ||
| type 2 diabetes | encapsulated cinnamon power | Khan et al., 2003; Mang et al., 2006; Crawford, 2009; Akilen et al., 2010; Wainstein et al., 2011; Talaei et al., 2017; Mirmiran et al., 2019; Zare et al., 2019 |
| cinnamon extract | Lu et al., 2012; Ranasinghe et al., 2017a | |
| cinnamon in black tea | Azimi et al., 2016 | |
| polycystic ovary syndrome | encapsulated cinnamon power | Kort and Lobo, 2014; Borzoei et al., 2018; Hajimonfarednejad et al., 2018 |
| dysmenorrhea (painful periods) | Jahangirifar et al., 2018 | |
| metabolic syndrome | Gupta Jain et al., 2017 | |
| migraine attacks and inflammatory markers | Zareie et al., 2020 | |
| pharmacodynamic properties and safety | Ranasinghe et al., 2017b | |
| postmenopausal type 2 Diabetes | Vanschoonbeek et al., 2006 | |
| overweight or obese pre-diabetic subjects | Liu et al., 2015 | |
| non-alcoholic fatty liver disease | Askari et al., 2014 | |
| Ceylon cinnamon does not affect postprandial plasma glucose or insulin | Wickenberg et al., 2012 | |
| overweight or obese subjects | cinnamon extract | Roussel et al., 2009 |
| effect on electrocardiographic parameters | Pender et al., 2018 | |
| perineal pain and healing of episiotomy | Mohammadi et al., 2014 | |
| Helicobacter pylori | Nir et al., 2000 | |
| type 1 diabetes | cinnamon pill | Altschuler et al., 2007 |
| overactive bladder | cinnamon patch | Chen et al., 2021 |
| postprandial (after meals) capillary blood glucose level | cinnamon tea | Bernardo et al., 2015 |
Selected clinical studies on Ceylon cinnamon.
Table 3
| Disease/condition or observed effect | Dosage form | References |
|---|---|---|
| Hops | ||
| quality of sleep | standardized extracts of Valeriana officinalis, Passiflora incarnate, and Humulus lupulus | Maroo et al., 2013 |
| linolenic and linoleic acids in association with Humulus lupulus extract. | Cornu et al., 2010 | |
| valerian/hop extract combination | Müller-Limmroth and Ehrenstein, 1977; Koetter et al., 2007; Dimpfel and Suter, 2008 | |
| Vigilance | tablets containing valerian and hops | Gerhard et al., 1996 |
| menopausal symptoms | hop extract | Erkkola et al., 2010; van Breemen et al., 2020 |
| hop tablets | Aghamiri et al., 2016 | |
| appetite suppression | hop flower extract suspended in canola oil | Walker et al., 2019 |
| body fat | matured hop extract | Morimoto-Kobayashi et al., 2016; Suzuki et al., 2018 |
| dental plaque regrowth | hop bract polyphenols | Shinada et al., 2007 |
| clinical safety and efficacy | combination of iso-alpha acids from hops, rosemary, and oleanolic acid | Minich et al., 2007 |
| self-reported depression, anxiety, and stress levels | dry hop extract | Kyrou et al., 2017 |
| overactive bladder | combination of seed oil from Uromedic pumpkin, Rhus aromatica (bark extract, and hop cone extract) | Gauruder-Burmester et al., 2019 |
| intestinal conversion of isoxanthohumol in 8-prenylnaringenin | dose of isoxanthohumol | Possemiers et al., 2006 |
| endothelial functions | isomerized hop extract | Tomita et al., 2017 |
Selected clinical studies on hops.
In conclusion, we recommend future experiments on hops and Ceylon cinnamon to evaluate their potential in limiting overshooting immune reactions in COVID-19. We work mainly with ethanolic extracts in cell culture. However, encapsulated cinnamon powder or water extracts of hops may be better suited for administration to patients. We suggest that appropriate doses for treatment of COVID-19 patients may be determined with reference to the clinical studies that have used hops and Ceylon cinnamon to treat other conditions.
Statements
Author contributions
KL and MA initiated the idea of the review and were involved in the manuscript writing. J-FN was involved in manuscript refinement. NO was involved in the literature search. All authors contributed to the article and approved the submitted version.
Acknowledgments
We thank Ulrich Pöschl very much for his helpful support.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AckermannM.VerledenS. E.KuehnelM.HaverichA.WelteT.LaengerF.et al. (2020). Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med.383, 120–128. 10.1056/NEJMoa2015432
2
AghamiriV.MirghafourvandM.Mohammad-Alizadeh-CharandabiS.NazemiyehH. (2016). The effect of Hop (Humulus lupulus L.) on early menopausal symptoms and hot flashes: a randomized placebo-controlled trial. Complement. Ther. Clin. Pract.23, 130–135. 10.1016/j.ctcp.2015.05.001
3
AkilenR.TsiamiA.DevendraD.RobinsonN. (2010). Glycated haemoglobin and blood pressure-lowering effect of cinnamon in multi-ethnic Type 2 diabetic patients in the UK: a randomized, placebo-controlled, double-blind clinical trial. Diabet. Med.27, 1159–1167. 10.1111/j.1464-5491.2010.03079.x
4
AltschulerJ. A.CasellaS. J.MackenzieT. A.CurtisK. M. (2007). The effect of cinnamon on A1C among adolescents with type 1 diabetes. Diabetes Care30, 813–816. 10.2337/dc06-1871
5
AskariF.RashidkhaniB.HekmatdoostA. (2014). Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr. Res.34, 143–148. 10.1016/j.nutres.2013.11.005
6
AzimiP.GhiasvandR.FeiziA.HosseinzadehJ.BahreynianM.HaririM.et al. (2016). Effect of cinnamon, cardamom, saffron, and ginger consumption on blood pressure and a marker of endothelial function in patients with type 2 diabetes mellitus: a randomized controlled clinical trial. Blood Press.25, 133–140. 10.3109/08037051.2015.1111020
7
BernardoM. A.SilvaM. L.SantosE.MoncadaM. M.BritoJ.ProençaL.et al. (2015). Effect of cinnamon tea on postprandial glucose concentration. J. Diabetes Res.2015:913651. 10.1155/2015/913651
8
BorzoeiA.RafrafM.Asghari-JafarabadiM. (2018). Cinnamon improves metabolic factors without detectable effects on adiponectin in women with polycystic ovary syndrome. Asia Pac. J. Clin. Nutr.27, 556–563. 10.6133/apjcn.062017.13
9
BuckwoldV. E.WilsonR. J.NalcaA.BeerB. B.VossT. G.TurpinJ. A.et al. (2004). Antiviral activity of hop constituents against a series of DNA and RNA viruses. Antiviral Res.61, 57–62. 10.1016/S0166-3542(03)00155-4
10
CermakP.OlsovskaJ.MikyskaA.DusekM.KadleckovaZ.VanicekJ.et al. (2017). Strong antimicrobial activity of xanthohumol and other derivatives from hops (Humulus lupulus L.) on gut anaerobic bacteria. Apmis125, 1033–1038. 10.1111/apm.12747
11
ChenL. L.ShenY. C.KeC. C.ImtiyazZ.ChenH. I.ChangC. H.et al. (2021). Efficacy of cinnamon patch treatment for alleviating symptoms of overactive bladder: a double-blind, randomized, placebo-controlled trial. Phytomedicine80:153380. 10.1016/j.phymed.2020.153380
12
CornuC.RemontetL.Noel-BaronF.NicolasA.Feugier-FavierN.RoyP.et al. (2010). A dietary supplement to improve the quality of sleep: a randomized placebo controlled trial. BMC Complement. Altern. Med.10:29. 10.1186/1472-6882-10-29
13
CrawfordP. (2009). Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial. J. Am. Board Fam. Med.22, 507–512. 10.3122/jabfm.2009.05.080093
14
DietzB. M.HagosG. K.EskraJ. N.WijewickramaG. T.AndersonJ. R.NikolicD.et al. (2013). Differential regulation of detoxification enzymes in hepatic and mammary tissue by hops (Humulus lupulus) in vitro and in vivo. Mol. Nutr. Food Res.57, 1055–1066. 10.1002/mnfr.201200534
15
DietzB. M.KangY. H.LiuG.EgglerA. L.YaoP.ChadwickL. R.et al. (2005). Xanthohumol isolated from Humulus lupulus Inhibits menadione-induced DNA damage through induction of quinone reductase. Chem. Res. Toxicol.18, 1296–1305. 10.1021/tx050058x
16
DimpfelW.SuterA. (2008). Sleep improving effects of a single dose administration of a valerian/hops fluid extract–a double blind, randomized, placebo-controlled sleep-EEG study in a parallel design using electrohypnograms. Eur. J. Med. Res.13, 200–204. 10.1055/s-2008-1047853
17
DornC.HeilmannJ.HellerbrandC. (2012). Protective effect of xanthohumol on toxin-induced liver inflammation and fibrosis. Int. J. Clin. Exp. Pathol.5, 29–36. 10.1055/s-0031-1295738
18
DoyleA. A.StephensJ. C. (2019). A review of cinnamaldehyde and its derivatives as antibacterial agents. Fitoterapia139:104405. 10.1016/j.fitote.2019.104405
19
ErkkolaR.VervarckeS.VansteelandtS.RompottiP.De KeukeleireD.HeyerickA. (2010). A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts. Phytomedicine17, 389–396. 10.1016/j.phymed.2010.01.007
20
FerkF.MišíkM.NersesyanA.PichlerC.JägerW.SzekeresT.et al. (2016). Impact of xanthohumol (a prenylated flavonoid from hops) on DNA stability and other health-related biochemical parameters: results of human intervention trials. Mol. Nutr. Food Res.60, 773–786. 10.1002/mnfr.201500355
21
FuW.ChenL.WangZ.ZhaoC.ChenG.LiuX.et al. (2016). Determination of the binding mode for anti-inflammatory natural product xanthohumol with myeloid differentiation protein 2. Drug Des. Dev. Ther.10, 455–463. 10.2147/DDDT.S98466
22
FuchimotoJ.KojimaT.OkabayashiT.MasakiT.OgasawaraN.ObataK.et al. (2013). Humulone suppresses replication of respiratory syncytial virus and release of IL-8 and RANTES in normal human nasal epithelial cells. Med. Mol. Morphol.46, 203–209. 10.1007/s00795-013-0024-1
23
Gauruder-BurmesterA.HeimS.PatzB.SeibtS. (2019). Cucurbita pepo-Rhus aromatica-Humulus lupulus combination reduces overactive bladder symptoms in women–a noninterventional study. Planta Med.85, 1044–1053. 10.1055/a-0946-2280
24
GerhardU.LinnenbrinkN.GeorghiadouC.HobiV. (1996). [Vigilance-decreasing effects of 2 plant-derived sedatives]. Praxis (Bern 1994)85, 473–481.
25
GerhäuserC. (2005). Broad spectrum anti-infective potential of xanthohumol from hop (Humulus lupulus L.) in comparison with activities of other hop constituents and xanthohumol metabolites. Mol. Nutr. Food Res.49, 827–831. 10.1002/mnfr.200500091
26
Gupta JainS.PuriS.MisraA.GulatiS.ManiK. (2017). Effect of oral cinnamon intervention on metabolic profile and body composition of Asian Indians with metabolic syndrome: a randomized double-blind control trial. Lipids Health Dis.16:113. 10.1186/s12944-017-0504-8
27
HajimonfarednejadM.NimrouziM.HeydariM.ZarshenasM. M.RaeeM. J.JahromiB. N. (2018). Insulin resistance improvement by cinnamon powder in polycystic ovary syndrome: a randomized double-blind placebo controlled clinical trial. Phytother. Res.32, 276–283. 10.1002/ptr.5970
28
HallA. J.BabishJ. G.DarlandG. K.CarrollB. J.KondaV. R.LermanR. H.et al. (2008). Safety, efficacy, and anti-inflammatory activity of rho iso-alpha-acids from hops. Phytochemistry69, 1534–1547. 10.1016/j.phytochem.2008.02.001
29
HenekaM. T.GolenbockD.LatzE.MorganD.BrownR. (2020). Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res. Ther.12:69. 10.1186/s13195-020-00640-3
30
HorbyP.LimW. S.EmbersonJ. R.MafhamM.BellJ. L.LinsellL.et al. (2020). Dexamethasone in hospitalized patients with Covid-19–preliminary report. N. Engl. J. Med. 10.1101/2020.06.22.20137273
31
JahangirifarM.TaebiM.DolatianM. (2018). The effect of cinnamon on primary dysmenorrhea: a randomized, double-blind clinical trial. Complement. Ther. Clin. Pract.33, 56–60. 10.1016/j.ctcp.2018.08.001
32
KanuriG.WeberS.VolynetsV.SprussA.BischoffS. C.BergheimI. (2009). Cinnamon extract protects against acute alcohol-induced liver steatosis in mice. J. Nutr.139, 482–487. 10.3945/jn.108.100495
33
KhanA.SafdarM.Ali KhanM. M.KhattakK. N.AndersonR. A. (2003). Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care26, 3215–3218. 10.2337/diacare.26.12.3215
34
Knez HrncicM.SpaningerE.KosirI. J.KnezZ.BrenU. (2019). Hop compounds: extraction techniques, chemical analyses, antioxidative, antimicrobial, and anticarcinogenic effects. Nutrients11:257. 10.3390/nu11020257
35
KoetterU.SchraderE.KäufelerR.BrattströmA. (2007). A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytother. Res.21, 847–851. 10.1002/ptr.2167
36
KortD. H.LoboR. A. (2014). Preliminary evidence that cinnamon improves menstrual cyclicity in women with polycystic ovary syndrome: a randomized controlled trial. Am. J. Obstet. Gynecol.211, 487.e1–487.e6. 10.1016/j.ajog.2014.05.009
37
KyrouI.ChristouA.PanagiotakosD.StefanakiC.SkenderiK.KatsanaK.et al. (2017). Effects of a hops (Humulus lupulus L.) dry extract supplement on self-reported depression, anxiety, and stress levels in apparently healthy young adults: a randomized, placebo-controlled, double-blind, crossover pilot study. Hormones (Athens)16, 171–180. 10.14310/horm.2002.1738
38
LeeI. S.LimJ.GalJ.KangJ. C.KimH. J.KangB. Y.et al. (2011). Anti-inflammatory activity of xanthohumol involves heme oxygenase-1 induction via NRF2-ARE signaling in microglial BV2 cells. Neurochem. Int.58, 153–160. 10.1016/j.neuint.2010.11.008
39
LeeJ. C.KunduJ. K.HwangD. M.NaH. K.SurhY. J. (2007). Humulone inhibits phorbol ester-induced COX-2 expression in mouse skin by blocking activation of NF-kappaB and AP-1: IkappaB kinase and c-Jun-N-terminal kinase as respective potential upstream targets. Carcinogenesis28, 1491–1498. 10.1093/carcin/bgm054
40
LinM.XiangD.ChenX.HuoH. (2019). Role of characteristic components of humulus lupulus in promoting human health. J. Agric. Food Chem.67, 8291–8302. 10.1021/acs.jafc.9b03780
41
LiuX.BaiJ.JiangC.SongZ.ZhaoY.NauwynckH.et al. (2019). Therapeutic effect of Xanthohumol against highly pathogenic porcine reproductive and respiratory syndrome viruses. Vet. Microbiol.238:108431. 10.1016/j.vetmic.2019.108431
42
LiuY.CotillardA.VatierC.BastardJ. P.FellahiS.StévantM.et al. (2015). A dietary supplement containing cinnamon, chromium, and carnosine decreases fasting plasma glucose and increases lean mass in overweight or obese pre-diabetic subjects: a randomized, placebo-controlled trial. PLoS ONE10:e0138646. 10.1145/2818302
43
LongM.TaoS.Rojo De La VegaM.JiangT.WenQ.ParkS. L.et al. (2015). Nrf2-dependent suppression of azoxymethane/dextran sulfate sodium-induced colon carcinogenesis by the cinnamon-derived dietary factor cinnamaldehyde. Cancer Prev. Res. (Phila)8, 444–454. 10.1158/1940-6207.CAPR-14-0359
44
LuJ.ZhangK.NamS.AndersonR. A.JoveR.WenW. (2010). Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling. Carcinogenesis31, 481–488. 10.1093/carcin/bgp292
45
LuT.ShengH.WuJ.ChengY.ZhuJ.ChenY. (2012). Cinnamon extract improves fasting blood glucose and glycosylated hemoglobin level in Chinese patients with type 2 diabetes. Nutr. Res.32, 408–412. 10.1016/j.nutres.2012.05.003
46
LucasK.MaesM. (2013). Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol. Neurobiol.48, 190–204. 10.1007/s12035-013-8425-7
47
MangB.WoltersM.SchmittB.KelbK.LichtinghagenR.StichtenothD. O.et al. (2006). Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur. J. Clin. Invest.36, 340–344. 10.1111/j.1365-2362.2006.01629.x
48
MarooN.HazraA.DasT. (2013). Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial. Indian J. Pharmacol.45, 34–39. 10.4103/0253-7613.106432
49
MinichD. M.BlandJ. S.KatkeJ.DarlandG.HallA.LermanR. H.et al. (2007). Clinical safety and efficacy of NG440: a novel combination of rho iso-alpha acids from hops, rosemary, and oleanolic acid for inflammatory conditions. Can. J. Physiol. Pharmacol.85, 872–883. 10.1139/Y07-055
50
MirmiranP.DavariM.HashemiR.HedayatiM.SahranavardS.BahreiniS.et al. (2019). A randomized controlled trial to determining the effect of cinnamon on the plasma levels of soluble forms of vascular adhesion molecules in type 2 diabetes mellitus. Eur. J. Clin. Nutr.73, 1605–1612. 10.1038/s41430-019-0523-9
51
MohammadiA.Mohammad-Alizadeh-CharandabiS.MirghafourvandM.JavadzadehY.FardiazarZ.Effati-DaryaniF. (2014). Effects of cinnamon on perineal pain and healing of episiotomy: a randomized placebo-controlled trial. J. Integr. Med.12, 359–366. 10.1016/S2095-4964(14)60025-X
52
Morimoto-KobayashiY.OharaK.AshigaiH.KanayaT.KoizumiK.ManabeF.et al. (2016). Matured hop extract reduces body fat in healthy overweight humans: a randomized, double-blind, placebo-controlled parallel group study. Nutr. J.15:25. 10.1186/s12937-016-0144-2
53
Müller-LimmrothW.EhrensteinW. (1977). [Experimental studies of the effects of Seda-Kneipp on the sleep of sleep disturbed subjects; implications for the treatment of different sleep disturbances (author's transl)]. Med. Klin.72, 1119–1125.
54
NatarajanP.KattaS.AndreiI.Babu Rao AmbatiV.LeonidaM.HaasG. J. (2008). Positive antibacterial co-action between hop (Humulus lupulus) constituents and selected antibiotics. Phytomedicine15, 194–201. 10.1016/j.phymed.2007.10.008
55
NayakI. N.ChintaR.JettiR. (2017). Anti-atherosclerotic potential of aqueous extract of cinnamomum zeylanicum Bark against glucocorticoid induced atherosclerosis in wistar rats. J. Clin. Diagn. Res.11, Fc19–fc23. 10.7860/JCDR/2017/23910.9864
56
NirY.PotasmanI.StermerE.TabakM.NeemanI. (2000). Controlled trial of the effect of cinnamon extract on Helicobacter pylori. Helicobacter5, 94–97. 10.1046/j.1523-5378.2000.00014.x
57
Oketch-RabahH. A.MarlesR. J.BrinckmannJ. A. (2018). Cinnamon and cassia nomenclature confusion: a challenge to the applicability of clinical data. Clin. Pharmacol. Ther.104, 435–445. 10.1002/cpt.1162
58
OseR.TuJ.SchinkA.MaxeinerJ.SchusterP.LucasK.et al. (2020). Cinnamon extract inhibits allergen-specific immune responses in human and murine allergy models. Clin. Exp. Allergy50, 41–50. 10.1111/cea.13507
59
PalamandS. R.AldenhoffJ. M. (1973). Bitter tasting compounds of beer. Chemistry and taste properties of some hop resin compounds. J. Agric. Food Chem.21, 535–543. 10.1021/jf60188a005
60
PatraK.JanaS.SarkarA.MandalD. P.BhattacharjeeS. (2019). The inhibition of hypoxia-induced angiogenesis and metastasis by cinnamaldehyde is mediated by decreasing HIF-1α protein synthesis via PI3K/Akt pathway. Biofactors45, 401–415. 10.1002/biof.1499
61
PenderD. N.CrawfordP. F.ClarkJ. M.CrawfordA. J.PratsA. A.ShahS. A. (2018). Effect of water-soluble cinnamon extract on electrocardiographic parameters: an analysis of the CiNNaMON trial. Complement. Ther. Med.41, 302–305. 10.1016/j.ctim.2018.10.009
62
PintoC.CesteroJ. J.Rodríguez-GaldónB.MacíasP. (2014). Xanthohumol, a prenylated flavonoid from hops (Humulus lupulus L.), protects rat tissues against oxidative damage after acute ethanol administration. Toxicol. Rep.1, 726–733. 10.1016/j.toxrep.2014.09.004
63
PortincasaP.KrawczykM.MachillA.LammertF.Di CiaulaA. (2020). Hepatic consequences of COVID-19 infection. Lapping or biting?Eur. J. Intern. Med.77, 18–24. 10.1016/j.ejim.2020.05.035
64
PossemiersS.BolcaS.GrootaertC.HeyerickA.DecroosK.DhoogeW.et al. (2006). The prenylflavonoid isoxanthohumol from hops (Humulus lupulus L.) is activated into the potent phytoestrogen 8-prenylnaringenin in vitro and in the human intestine. J. Nutr.136, 1862–1867. 10.1093/jn/136.7.1862
65
PóvoaH. C. C.ChiancaG. C.IorioN. (2020). COVID-19: an alert to ventilator-associated bacterial pneumonia. Infect. Dis. Ther.9, 1–4. 10.1007/s40121-020-00306-5
66
RanasingheP.GalappaththyP.ConstantineG. R.JayawardenaR.WeeratungaH. D.PremakumaraS.et al. (2017a). Cinnamomum zeylanicum (Ceylon cinnamon) as a potential pharmaceutical agent for type-2 diabetes mellitus: study protocol for a randomized controlled trial. Trials18:446. 10.1186/s13063-017-2192-0
67
RanasingheP.JayawardenaR.PigeraS.WathurapathaW. S.WeeratungaH. D.PremakumaraG.et al. (2017b). Evaluation of pharmacodynamic properties and safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults: a phase I clinical trial. BMC Complement. Altern. Med.17:550. 10.1186/s12906-017-2067-7
68
RanasingheP.PigeraS.PremakumaraG. A.GalappaththyP.ConstantineG. R.KatulandaP. (2013). Medicinal properties of 'true' cinnamon (Cinnamomum zeylanicum): a systematic review. BMC Complement. Altern. Med.13:275. 10.1186/1472-6882-13-275
69
RenuK.PrasannaP. L.Valsala GopalakrishnanA. (2020). Coronaviruses pathogenesis, comorbidities, and multi-organ damage–a review. Life Sci.255:117839. 10.1016/j.lfs.2020.117839
70
RousselA. M.HiningerI.BenarabaR.ZiegenfussT. N.AndersonR. A. (2009). Antioxidant effects of a cinnamon extract in people with impaired fasting glucose that are overweight or obese. J. Am. Coll. Nutr.28, 16–21. 10.1080/07315724.2009.10719756
71
SaugspierM.DornC.ThaslerW. E.GehrigM.HeilmannJ.HellerbrandC. (2012). Hop bitter acids exhibit anti-fibrogenic effects on hepatic stellate cells in vitro. Exp. Mol. Pathol.92, 222–228. 10.1016/j.yexmp.2011.11.005
72
SchinkA.NaumoskaK.KitanovskiZ.KampfC. J.Fröhlich-NowoiskyJ.ThinesE.et al. (2018a). Anti-inflammatory effects of cinnamon extract and identification of active compounds influencing the TLR2 and TLR4 signaling pathways. Food Funct.9, 5950–5964. 10.1039/C8FO01286E
73
SchinkA.NeumannJ.LeifkeA. L.ZieglerK.Fröhlich-NowoiskyJ.CremerC.et al. (2018b). Screening of herbal extracts for TLR2- and TLR4-dependent anti-inflammatory effects. PLoS ONE13:e0203907. 10.1371/journal.pone.0203907
74
ShinadaK.TagashiraM.WatanabeH.SopapornamornP.KanayamaA.KandaT.et al. (2007). Hop bract polyphenols reduced three-day dental plaque regrowth. J. Dent. Res.86, 848–851. 10.1177/154405910708600908
75
StevensJ. F.MirandaC. L.WolthersK. R.SchimerlikM.DeinzerM. L.BuhlerD. R. (2002). Identification and in vitro biological activities of hop proanthocyanidins: inhibition of nNOS activity and scavenging of reactive nitrogen species. J. Agric. Food Chem.50, 3435–3443. 10.1021/jf0116202
76
SuzukiS.YamazakiT.TakahashiC.KanekoY.Morimoto-KobayashiY.KatayamaM. (2018). The relationship between the effect of matured hop extract and physical activity on reducing body fat: re-analysis of data from a randomized, double-blind, placebo-controlled parallel group study. Nutr. J.17:98. 10.1186/s12937-018-0405-3
77
TalaeiB.AmouzegarA.SahranavardS.HedayatiM.MirmiranP.AziziF. (2017). Effects of cinnamon consumption on glycemic indicators, advanced glycation end products, and antioxidant status in type 2 diabetic patients. Nutrients9:991. 10.3390/nu9090991
78
TomitaJ.MochizukiS.FujimotoS.KashiharaN.AkasakaT.TanimotoM.et al. (2017). Acute improvement of endothelial functions after oral ingestion of isohumulones, bitter components of beer. Biochem. Biophys. Res. Commun.484, 740–745. 10.1016/j.bbrc.2017.01.133
79
van BreemenR. B.ChenL.Tonsing-CarterA.BanuvarS.BarengoltsE.VianaM.et al. (2020). Pharmacokinetic interactions of a hop dietary supplement with drug metabolism in perimenopausal and postmenopausal women. J. Agric. Food Chem.68, 5212–5220. 10.1021/acs.jafc.0c01077
80
VanschoonbeekK.ThomassenB. J.SendenJ. M.WodzigW. K.Van LoonL. J. (2006). Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J. Nutr.136, 977–980. 10.1093/jn/136.4.977
81
VasconcelosN. G.CrodaJ.SimionattoS. (2018). Antibacterial mechanisms of cinnamon and its constituents: a review. Microb. Pathog.120, 198–203. 10.1016/j.micpath.2018.04.036
82
WainsteinJ.SternN.HellerS.BoazM. (2011). Dietary cinnamon supplementation and changes in systolic blood pressure in subjects with type 2 diabetes. J. Med. Food14, 1505–1510. 10.1089/jmf.2010.0300
83
WalkerE.LoK.ThamS.PahlM.LomiwesD.CooneyJ.et al. (2019). New Zealand bitter hops extract reduces hunger during a 24 h water only fast. Nutrients11:2754. 10.3390/nu11112754
84
WangT.DuZ.ZhuF.CaoZ.AnY.GaoY.et al. (2020). Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet395:e52. 10.1016/S0140-6736(20)30558-4
85
WeberN.BiehlerK.SchwabeK.HaarhausB.QuirinK. W.FrankU.et al. (2019). Hop extract acts as an antioxidant with antimicrobial effects against propionibacterium acnes and staphylococcus aureus. Molecules24:223. 10.3390/molecules24020223
86
WickenbergJ.LindstedtS.BerntorpK.NilssonJ.HlebowiczJ. (2012). Ceylon cinnamon does not affect postprandial plasma glucose or insulin in subjects with impaired glucose tolerance. Br. J. Nutr.107, 1845–1849. 10.1017/S0007114511005113
87
WondrakG. T.VilleneuveN. F.LamoreS. D.BauseA. S.JiangT.ZhangD. D. (2010). The cinnamon-derived dietary factor cinnamic aldehyde activates the Nrf2-dependent antioxidant response in human epithelial colon cells. Molecules15, 3338–3355. 10.3390/molecules15053338
88
WuC. P.AdhiF.HighlandK. (2020). Recognition and management of respiratory coinfection and secondary bacterial pneumonia in patients with COVID-19. Cleve. Clin. J. Med. 87, 659–663. 10.3949/ccjm.87a.ccc015
89
XinG.WeiZ.JiC.ZhengH.GuJ.MaL.et al. (2017). Xanthohumol isolated from Humulus lupulus prevents thrombosis without increased bleeding risk by inhibiting platelet activation and mtDNA release. Free Radic. Biol. Med.108, 247–257. 10.1016/j.freeradbiomed.2017.02.018
90
YamamotoK.WangJ.YamamotoS.TobeH. (2000). Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid. FEBS Lett.465, 103–106. 10.1016/S0014-5793(99)01727-5
91
YamamotoM.KenslerT. W.MotohashiH. (2018). The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol. Rev.98, 1169–1203. 10.1152/physrev.00023.2017
92
YaoJ.ZhangB.GeC.PengS.FangJ. (2015). Xanthohumol, a polyphenol chalcone present in hops, activating Nrf2 enzymes to confer protection against oxidative damage in PC12 cells. J. Agric. Food Chem.63, 1521–1531. 10.1021/jf505075n
93
YeQ.WangB.MaoJ. (2020). The pathogenesis and treatment of the “Cytokine Storm” in COVID-19. J. Infect.80, 607–613. 10.1016/j.jinf.2020.03.037
94
ZareR.NadjarzadehA.ZarshenasM. M.ShamsM.HeydariM. (2019). Efficacy of cinnamon in patients with type II diabetes mellitus: a randomized controlled clinical trial. Clin. Nutr.38, 549–556. 10.1016/j.clnu.2018.03.003
95
ZareieA.SahebkarA.KhorvashF.BagherniyaM.HasanzadehA.AskariG. (2020). Effect of cinnamon on migraine attacks and inflammatory markers: a randomized double-blind placebo-controlled trial. Phytother. Res.34, 2945–2952. 10.1002/ptr.6721
96
ZhangH.ZhangY.WuJ.LiY.ZhouX.LiX.et al. (2020). Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg. Microbes Infect.9, 1958–1964. 10.1080/22221751.2020.1812437
97
ZhangN.LiuZ.HanQ.ChenJ.LvY. (2010). Xanthohumol enhances antiviral effect of interferon α-2b against bovine viral diarrhea virus, a surrogate of hepatitis C virus. Phytomedicine17, 310–316. 10.1016/j.phymed.2009.08.005
Summary
Keywords
COVID-19, Ceylon cinnamon, hops, anti-inflammatory (activity), angiogenesis inhibition
Citation
Lucas K, Fröhlich-Nowoisky J, Oppitz N and Ackermann M (2021) Cinnamon and Hop Extracts as Potential Immunomodulators for Severe COVID-19 Cases. Front. Plant Sci. 12:589783. doi: 10.3389/fpls.2021.589783
Received
31 July 2020
Accepted
02 February 2021
Published
26 February 2021
Volume
12 - 2021
Edited by
Linda Avesani, University of Verona, Italy
Reviewed by
Dayakar Venkata Badri, Hill's Pet Nutrition, Inc., United States; Jim Tokuhisa, Virginia Tech, United States
Updates
Copyright
© 2021 Lucas, Fröhlich-Nowoisky, Oppitz and Ackermann.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kurt Lucas k.lucas@mpic.de
This article was submitted to Plant Metabolism and Chemodiversity, a section of the journal Frontiers in Plant Science
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.